Deitra Williams

Deitra Williams serves as a key procurement professional within the ASPR BARDA Division of Contracts Management and Acquisition, supporting the Department of Health and Human Services’ mission to accelerate the development and scalable production of medical countermeasures against biological, chemical, radiological, and nuclear threats. She manages complex acquisition strategies for advanced biomedical R&D and manufacturing capabilities, ensuring timely delivery of critical public health preparedness assets. Her work spans the full contract lifecycle—from needs analysis and solicitation to award and performance oversight—focusing on high-priority national security and pandemic response initiatives. Williams collaborates with a diverse ecosystem of contractors, primarily biotechnology research firms and biological product manufacturers, many of which possess specialized expertise in vaccine development, therapeutic platforms, and GMP-scale production. Her procurement patterns reflect a preference for established industry partners with proven capabilities in rapid-response biomanufacturing and clinical-stage development, fostering long-term partnerships with entities capable of meeting stringent FDA and BARDA regulatory requirements. While no single contractor dominates her portfolio, she consistently engages vendors with prior experience in federal emergency response programs. Her contracting approach is non-set-aside focused, with 100% of acquisitions conducted under full and open competition, indicating a priority on technical capability and readiness over socioeconomic preferences. This reflects the urgency and technical complexity of BARDA’s mission, where speed, scalability, and regulatory compliance outweigh traditional small business set-asides. Her primary procurement focus lies in NAICS 541714 (Biotechnology R&D) and 325414 (Biological Product Manufacturing), underscoring deep expertise in preclinical and clinical-stage medical countermeasures, including monoclonal antibodies, antivirals, and novel vaccine platforms. She routinely procures services involving biosafety level containment, process validation, and cold-chain logistics, demonstrating advanced technical fluency in the biopharmaceutical acquisition domain.